These NCCN Guidelines Insights highlight the important updates specific to the management of HER2-postive metastatic breast cancer in the 2013 version of the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer.

Join Harold Burstein, MD, PhD (Medical Oncologist) and Jennifer Bellon, MD (Radiation Oncologist) as they present their multidisciplinary expertise on a range of cases pertaining to triple negative breast cancer.

The phosphoinositide-3-kinase (PI3-kinase)-Akt-mTOR pathway is a central signal transduction pathway that regulates many critical aspects of normal and cancer physiology, including cell proliferation, apoptosis, cell morphology and migration, protein synthesis, and integration of metabolism.

Join Harold Burstein, MD, PhD (Medical Oncologist) and Jennifer Bellon, MD (Radiation Oncologist) as they present their multidisciplinary expertise on a range of cases pertaining to triple negative breast cancer.

Breast cancer is a common manifestation of an underlying genetic susceptibility to cancer, and 5% to 10% of all breast cancers are associated with a germline mutation in a known risk allele.

The 2013 Nursing Program: Advancing Oncology Nursing™ webinar series will provide the oncology nurse with comprehensive and clinically relevant information regarding the management of patients with cancer.

Decisions regarding adjuvant chemotherapy for patients with estrogen receptor (ER)–positive HER2-negative lymph node–negative breast cancer have traditionally relied on clinical and pathologic parameters.

The Oncotype DX, PAM50, and MammaPrint are multigene tests that are being used clinically for early-stage breast cancer to predict recurrence risk and guide adjuvant chemotherapy decisions.

This recorded webinar series is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Breast and Ovarian Cancer, collectively known as Women’s Health Cancers.

This recorded webinar series is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Breast and Ovarian Cancer, collectively known as Women’s Health Cancers.